Influence of the selective COX-2 inhibitor celecoxib on sex differences in blood pressure and albuminuria in spontaneously hypertensive rats

Prostaglandins and Other Lipid Mediators

Volumn 135, Issue , 2018, Pages 16-20

  Elmarakby, Ahmed A ^a,d   Katary, Mohamed ^a,e   Pollock, Jennifer S ^c   Sullivan, Jennifer C ^b  

^a AUGUSTA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d MANSOURA UNIVERSITY   (Egypt)

^e Damanhour University   (Egypt)

Author keywords

Albuminuria; Blood pressure; Celecoxib; Oxidative stress; Prostaglandin metabolites; Sex difference; SHR

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CELECOXIB; CYCLOOXYGENASE 2; HYDROGEN PEROXIDE; PROSTACYCLIN; PROSTAGLANDIN E2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOXANE A2; THROMBOXANE B2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PROSTAGLANDIN RELEASE; PROSTAGLANDIN URINE LEVEL; RAT; SEX DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY; URINARY EXCRETION; ANIMAL; FEMALE; HYPERTENSION; MALE; METABOLISM; SEX FACTOR;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HYPERTENSION; MALE; PROSTAGLANDINS; RATS; RATS, INBRED SHR; SEX FACTORS;

EID: 85041551465     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2018.02.002     Document Type: Article

References (35)

1. Sandberg, K., Ji, H., Sex differences in primary hypertension. Biol. Sex Differ., 3(1), 2012, 7.
2. Dasinger, J.H., Alexander, B.T., Gender differences in developmental programming of cardiovascular diseases. Clin. Sci. (London) 130:5 (2016), 337–348.
3. Bubb, K.J., Khambata, R.S., Ahluwalia, A., Sexual dimorphism in rodent models of hypertension and atherosclerosis. Br. J. Pharmacol. 167:2 (2012), 298–312.
4. Jia, Z., Zhang, Y., Ding, G., Heiney, K.M., Huang, S., Zhang, A., Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury. Mediators Inflamm., 2015, 2015, 147894.
5. Hao, C.M., Breyer, M.D., Physiological regulation of prostaglandins in the kidney. Annu. Rev. Physiol. 70 (2008), 357–377.
6. Cipollone, F., Patrono, C., Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?. Arterioscler. Thromb. Vasc. Biol. 22:10 (2002), 1516–1518.
7. Sullivan, J.C., Sasser, J.M., Pollock, D.M., Pollock, J.S., Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. Hypertension 45:3 (2005), 406–411.
8. Reckelhoff, J.F., Zhang, H., Srivastava, K., Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension 35:1 Pt 2 (2000), 480–483.
9. Sullivan, J.C., Semprun-Prieto, L., Boesen, E.I., Pollock, D.M., Pollock, J.S., Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:4 (2007), R1573–9.
10. Ricciotti, E., FitzGerald, G.A., Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31:5 (2011), 986–1000.
11. Hocherl, K., Endemann, D., Kammerl, M.C., Grobecker, H.F., Kurtz, A., Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br. J. Pharmacol. 136:8 (2002), 1117–1126.
12. Chan, C.C., Reid, C.M., Aw, T.J., Liew, D., Haas, S.J., Krum, H., Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J. Hypertens. 27:12 (2009), 2332–2341.
13. Sullivan, J.C., Sasser, J.M., Pollock, J.S., Sexual dimorphism in oxidant status in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:2 (2007), R764–8.
14. Fortepiani, L.A., Reckelhoff, J.F., Role of oxidative stress in the sex differences in blood pressure in spontaneously hypertensive rats. J. Hypertens. 23:4 (2005), 801–805.
15. Widlansky, M.E., Price, D.T., Gokce, N., Eberhardt, R.T., Duffy, S.J., Holbrook, M., Maxwell, C., Palmisano, J., Keaney, J.F. Jr., Morrow, J.D., Vita, J.A., Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42:3 (2003), 310–315.
16. Tomida, T., Numaguchi, Y., Nishimoto, Y., Tsuzuki, M., Hayashi, Y., Imai, H., Matsui, H., Okumura, K., Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J. Hypertens. 21:3 (2003), 601–609.
17. El-Gowelli, H.M., Ibrahim, K.S., El-Yazbi, A.F., El-Mas, M.M., Role of NADPHox/Rho-kinase signaling in the cyclosporine-NSAIDs interactions on blood pressure and baroreflexes in female rats. Life Sci. 185 (2017), 15–22.
18. El-Yazbi, A.F., Ibrahim, K.S., El-Gowelli, H.M., El-Deeb, N.M., El-Mas, M.M., Modulation by NADPH oxidase of the chronic cardiovascular and autonomic interaction between cyclosporine and NSAIDs in female rats. Eur. J. Pharmacol. 806 (2017), 96–104.
19. Bhatia, K., Elmarakby, A.A., El-Remessy, A.B., Sullivan, J.C., Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats. Am. J. Physiol. Regul., Integr. Comp. Physiol. 302:2 (2012), R274–R282.
20. Sullivan, J.C., Bhatia, K., Yamamoto, T., Elmarakby, A.A., Angiotensin (1–7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension 56:4 (2010), 658–666.
21. Beaudin, A.E., Pun, M., Yang, C., Nicholl, D.D., Steinback, C.D., Slater, D.M., Wynne-Edwards, K.E., Hanly, P.J., Ahmed, S.B., Poulin, M.J., Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J. Am. Heart Assoc., 3(3), 2014, e000875.
22. Kim, G.H., Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press 6:1 (2008), 35–41.
23. Harris, R.C., Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney. Trans. Am. Clin. Climatol. Assoc. 124 (2013), 139–151.
24. Qi, Z., Cai, H., Morrow, J.D., Breyer, M.D., Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 48:2 (2006), 323–328.
25. Avendano, M.S., Martinez-Revelles, S., Aguado, A., Simoes, M.R., Gonzalez-Amor, M., Palacios, R., Guillem-Llobat, P., Vassallo, D.V., Vila, L., Garcia-Puig, J., Beltran, L.M., Alonso, M.J., Cachofeiro, M.V., Salaices, M., Briones, A.M., Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension. Br. J. Pharmacol. 173:9 (2016), 1541–1555.
26. Willette, R.N., Eybye, M.E., Olzinski, A.R., Behm, D.J., Aiyar, N., Maniscalco, K., Bentley, R.G., Coatney, R.W., Zhao, S., Westfall, T.D., Doe, C.P., Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J. Pharmacol. Exp. Ther. 330:3 (2009), 964–970.
27. Richter, C.M., Godes, M., Wagner, C., Maser-Gluth, C., Herzfeld, S., Dorn, M., Priem, F., Slowinski, T., Bauer, C., Schneider, W., Neumayer, H.H., Kurtz, A., Hocher, B., Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J. Hypertens. 22:1 (2004), 191–198.
28. Bayorh, M.A., Socci, R.R., Eatman, D., Wang, M., Thierry-Palmer, M., The role of gender in salt-induced hypertension. Clin. Exp. Hypertens. 23:3 (2001), 241–255.
29. Caughey, G.E., Cleland, L.G., Penglis, P.S., Gamble, J.R., James, M.J., Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J. Immunol. (Baltimore, Md.: 1950) 167:5 (2001), 2831–2838.
30. Harrison, D.G., Gongora, M.C., Guzik, T.J., Widder, J., Oxidative stress and hypertension. J. Am. Soc. Hypertens.: JASH 1:1 (2007), 30–44.
31. Montezano, A.C., Touyz, R.M., Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: a basic science update for the clinician. Can. J. Cardiol. 28:3 (2012), 288–295.
32. Rodrigo, R., Gonzalez, J., Paoletto, F., The role of oxidative stress in the pathophysiology of hypertension. Hypertens. Res. 34:4 (2011), 431–440.
33. Wilcox, C.S., Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?. Am. J. Physiol. Regul., Integr. Comp. Physiol. 289:4 (2005), R913–R935.
34. Hermann, M., Camici, G., Fratton, A., Hurlimann, D., Tanner, F.C., Hellermann, J.P., Fiedler, M., Thiery, J., Neidhart, M., Gay, R.E., Gay, S., Luscher, T.F., Ruschitzka, F., Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108:19 (2003), 2308–2311.
35. Capra, V., Back, M., Angiolillo, D.J., Cattaneo, M., Sakariassen, K.S., Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J. Thromb. Haemost. 12:2 (2014), 126–137.